Waystar to Acquire Iodine Software in $1.25B Deal to Enhance AI-Powered Healthcare Platform

Waystar Holding Corp. (NASDAQ:WAY) is one of the best IPO stocks to buy according to Wall Street analysts. On July 24, Waystar entered into a definitive agreement to acquire Iodine Software for an enterprise value of $1.25 billion. The deal is expected to be funded with an even split of cash and stock. Waystar shareholders will own ~92% of the new combined company, while Iodine equity holders will own about 8%.

Advent, which is the largest shareholder of Iodine, will receive Waystar shares and has agreed to an 18-month lock-up period post-closing. The acquisition is anticipated to close by the end of 2025, pending regulatory approvals. The acquisition aims to enhance Waystar’s cloud-based platform by integrating Iodine’s AI-powered clinical intelligence software.

A close-up of a hand tapping away at a keyboard, using the company’s software to carry out a transaction.

The combined entity is projected to serve 17 of the 20 US News Best Hospitals and increase Waystar’s total addressable market by over 15%. The integration will use Iodine’s AI engine, called IodineIQ, which trains on patient encounters and clinical data to automate tasks. The companies anticipate more than $15 million in cost synergies within the first two years after the closing.

Waystar Holding Corp. (NASDAQ:WAY) is a company that develops a cloud-based software solution for healthcare payments.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.